NEW YORK, April 26, 2017 /PRNewswire/ --
On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Biotechnology equities this morning: Cymabay Therapeutics Inc. (NASDAQ: CBAY), Benitec Biopharma Ltd (NASDAQ: BNTC), Sage Therapeutics Inc. (NASDAQ: SAGE), and Catalyst Biosciences Inc. (NASDAQ: CBIO). Download the free research reports on these stocks today:
Newark, California-based Cymabay Therapeutics Inc.'s stock finished Tuesday's session 2.47% lower at $3.56 with a total volume of 226,128 shares traded. Over the last three months and the previous one year, Cymabay Therapeutics' shares have surged 117.07% and 40.71%, respectively. The Company's shares are trading above its 200-day moving average by 51.55%. Shares of Cymabay Therapeutics, which focuses on developing therapies to treat metabolic diseases, have a Relative Strength Index (RSI) of 41.81. See our free and comprehensive research report on CBAY at:
North Sydney, Australia headquartered Benitec Biopharma Ltd's stock edged 0.38% higher, to close the day at $2.65. The stock recorded a trading volume of 77,012 shares. Benitec Biopharma's shares have surged 46.41% in the last three months and 61.59% in the previous one year. The Company's shares are trading 37.91% above its 200-day moving average. Additionally, shares of the Company, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia, the UK, and the US, have an RSI of 46.91. BNTC free research report PDF is just a click away at:
On Tuesday, shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. ended the session 0.71% higher at $73.37 with a total volume of 419,868 shares traded. Sage Therapeutics' shares have surged 17.41% in the last one month and 47.21% in the previous three months. Furthermore, the stock has rallied 94.20% in the past one year. The stock is trading 10.16% above its 50-day moving average and 44.63% above its 200-day moving average. Moreover, shares of the Company, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 60.24. Sign up for your complimentary report on SAGE at:
On Tuesday, shares in South San Francisco, California headquartered Catalyst Biosciences Inc. recorded a trading volume of 412,765 shares, which was lower than their three months average volume of 895,650 shares. The stock ended the day 2.41% higher at $4.67. Catalyst Biosciences' stock has rallied 733.93% in the last three months and 197.45% in the previous one year. The Company's shares are trading above its 200-day moving average by 99.22%. Furthermore, shares of Catalyst Biosciences, which focuses on developing medicines to address hematology indications, have an RSI of 40.91. Register for free on Stock-Callers.com and download the latest research report on CBIO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA